Trial Profile
Ibrutinib (Imbruvica), Bortezomib (Velcade) s.c., Rituximab, CHOP for the Treatment of Elderly Patients (Age 61-80 Years) With CD20+ Diffuse Large B-cell Lymphoma, IPI ≥ 2
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Plasmablastic lymphoma
- Focus Therapeutic Use
- Acronyms ImbruVeRCHOP
- 10 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2021 Planned End Date changed from 31 Mar 2023 to 31 Jan 2025.
- 25 Jan 2021 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2024.